Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
1995-2-6
pubmed:abstractText
Several studies in recent years have shown that the pyridinium crosslinks of collagen provide good urinary markers of collagen degradation, primarily reflecting bone resorption. Most studies, however, were based on time-consuming HPLC assays of the crosslinks. We now describe the development of an immunoassay (ELISA) based on a monoclonal antibody for free deoxypyridinoline (Dpd) and its use in healthy individuals and patients with bone-related disorders to measure the urinary excretion of Dpd as an improved assessment of bone resorption rate. The Dpd antibody exhibited less than 1% cross-reaction with free pyridinoline and was shown to react only with free Dpd in urine, having no significant interaction with peptide forms of the crosslinks. The intra- and interassay variations were less than 10 and 15%, respectively. A total of 402 urine samples from patients and healthy volunteers were analyzed by both the immunoassay and HPLC. The ELISA results were highly correlated with those for total Dpd measured by HPLC over the full range of sample groups (r = 0.95). In normal adults, the excretion of Dpd (mean +/- SD) was 4.7 +/- 1.6 nmol/mmol creatinine, with about fivefold higher excretion rates in children. For 31 osteoporotic patients, the ELISA Dpd values (median 6.7; range 3.0-13.5 nmol/mmol Cr) were significantly higher (p < 0.0001) than the corresponding values for age- and sex-matched controls (median 4.0; range 1.8-7.4). The difference between the groups was similar for total Dpd by HPLC (osteoporotic: mean 12.8, range 4.8-30.7; controls: 6.6, range 3.0-18.1; p < 0.0001).(ABSTRACT TRUNCATED AT 250 WORDS)
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
0884-0431
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1643-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:7817812-Adult, pubmed-meshheading:7817812-Aged, pubmed-meshheading:7817812-Aged, 80 and over, pubmed-meshheading:7817812-Aging, pubmed-meshheading:7817812-Amino Acids, pubmed-meshheading:7817812-Animals, pubmed-meshheading:7817812-Antibodies, Monoclonal, pubmed-meshheading:7817812-Antibody Specificity, pubmed-meshheading:7817812-Biological Markers, pubmed-meshheading:7817812-Bone Resorption, pubmed-meshheading:7817812-Breast Neoplasms, pubmed-meshheading:7817812-Chromatography, High Pressure Liquid, pubmed-meshheading:7817812-Enzyme-Linked Immunosorbent Assay, pubmed-meshheading:7817812-Female, pubmed-meshheading:7817812-Humans, pubmed-meshheading:7817812-Hyperparathyroidism, pubmed-meshheading:7817812-Kidney Failure, Chronic, pubmed-meshheading:7817812-Male, pubmed-meshheading:7817812-Mice, pubmed-meshheading:7817812-Middle Aged, pubmed-meshheading:7817812-Osteitis Deformans, pubmed-meshheading:7817812-Osteoporosis, pubmed-meshheading:7817812-Reproducibility of Results
pubmed:year
1994
pubmed:articleTitle
Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption.
pubmed:affiliation
Rowett Research Institute, Bucksburn, Aberdeen, Scotland.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Controlled Clinical Trial, Research Support, Non-U.S. Gov't